Revived by a single college student's letter, the Soothing Jelly Cleanser invites shoppers to exper...
* Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-te...
SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 19th that it c...
SEOUL, South Korea, April 17, 2026 /PRNewswire/ -- Penetrium Bioscience (KOSDAQ 187660) today annou...
Featuring its signature cream proven to endure the Sahara-like dryness of airplane cabins, the bran...
The evolution of a 10-year R&D heritage that previously swept top US luxury department stores. Meet...
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the...
Declares a strategic pivot to lead the post-patent immunotherapy combination era SEOUL, South Korea...
* Penetrium™ Achieves Historic Breakthrough * Overcoming Cold Tumor Failure and the Challenge of...
– Simultaneous treatment of primary and metastatic tumors by eliminating pseudo-resistance SEOUL, ...
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-...
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MO...
* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease...
* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patie...
* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients...
* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-bor...
* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience...
* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinica...
* Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients wi...
SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bios...